Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

Closed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced the initiation of their OptiZest study, ID: NCT06372470, and first patient recruitment.

OptiZest will investigate whether patients with hypertension can improve blood pressure control at home while receiving a personalized dose of Zestril (lisinopril). The study demonstrates an important stage in Closed Loop Medicine and Pharmanovia’s co- development partnership to progress the development and launch of a drug plus software combination version of a first-line anti-hypertensive in the UK, before phased global roll-out and additional therapeutic areas are added.

Hypertension is a leading preventable cause of morbidity and premature death worldwide, impacting over 1 in 4 men and 1 in 5 women, and costing the NHS alone over £2.1 billion/year. Medication and lifestyle interventions have been shown to significantly reduce associated health risks and improve quality of life, however, poor drug tolerability and treatment-related side effects significantly impact adherence and overall disease management.

By combining Closed Loop Medicine’s proprietary Software-as-a-Medical Device (SaMD) dose optimization technology and Pharmanovia’s established medicine brands, the companies aim to support patients and healthcare professionals through the development of an innovative intervention. The partnership is initially focused on addressing the clinical need in hypertension, which builds on recent trial data demonstrating the ability of Closed Loop Medicine’s SaMD platform to successfully control blood pressure, minimize side effects, and support medication adherence in participants, when linked with another first-line anti-hypertensive.

OptiZest is co-funded by both companies and led by Dr. Serge Engamba, GP and Clinical Research Lead at North Norfolk Primary Care. The study is also being supported by the National Institute for Health and Care Research.

Dr. Serge Engamba, Chief Investigator of OptiZest, GP, Clinical Research Lead at North Norfolk Primary Care and Deputy Specialty Lead at NIHR CRN East of England, commented: “Persistent high blood pressure can increase your risk of a number of serious and potentially life-threatening health conditions, such as heart attacks, strokes, kidney disease and even dementia. It is therefore crucial that doctors and patients work together to achieve optimal management of this condition. This pioneering research study offers an unprecedented opportunity to understand how effectively we can do this using innovative technologies and well-known medicines.”

Our dedication to advancing the quality of patient care is exemplified through our partnership with Pharmanovia and the initiation of the OptiZest study. This not only represents a milestone in hypertension management, but also underscores our broader mission to support healthcare systems in improving patient outcomes across diverse therapeutic areas.”

Dr. Hakim Yadi PhD OBE, CEO & Co-Founder, Closed Loop Medicine

Dr. James Burt, CEO of Pharmanovia, said: “OptiZest speaks to the heart of what we’re trying to do at Pharmanovia, which is to advance healthcare by innovating established medicines; enabling clinicians to efficiently personalize treatments for patients and seek to optimize the balance between efficacy and unwanted side effects. Starting by delivering much needed innovation to hypertension management, this study sets the stage for development and launch of one of the first drug and software combination products for hypertension.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Closed Loop Medicine. (2024, May 16). Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic. News-Medical. Retrieved on June 16, 2024 from https://www.news-medical.net/news/20240516/Closed-Loop-Medicine-and-Pharmanovia-commence-OptiZest-study-for-their-first-precision-medicine-combination-therapeutic.aspx.

  • MLA

    Closed Loop Medicine. "Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic". News-Medical. 16 June 2024. <https://www.news-medical.net/news/20240516/Closed-Loop-Medicine-and-Pharmanovia-commence-OptiZest-study-for-their-first-precision-medicine-combination-therapeutic.aspx>.

  • Chicago

    Closed Loop Medicine. "Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic". News-Medical. https://www.news-medical.net/news/20240516/Closed-Loop-Medicine-and-Pharmanovia-commence-OptiZest-study-for-their-first-precision-medicine-combination-therapeutic.aspx. (accessed June 16, 2024).

  • Harvard

    Closed Loop Medicine. 2024. Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic. News-Medical, viewed 16 June 2024, https://www.news-medical.net/news/20240516/Closed-Loop-Medicine-and-Pharmanovia-commence-OptiZest-study-for-their-first-precision-medicine-combination-therapeutic.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.